Paramount Skydance Secures $24B from Gulf Sovereign Wealth Funds for Warner Bros. Discovery Takeover 
SpaceX IPO: Retail Investors to Play Historic Role in Record-Breaking Public Offering 
Disney Plans to Cut 1,000 Jobs Amid Ongoing Restructuring Efforts 
UPS and Teamsters Reach Agreement to Limit Driver Severance Program 
Samsung Electronics Eyes Record Q1 Profit Amid AI-Driven Chip Boom 
Bank of America Identifies Top Asia-Pacific Semiconductor Stocks Poised for AI-Driven Growth 
OpenAI Executive Shake-Up Ahead of Anticipated 2026 IPO 
China Vanke Seeks Bond Extension Amid Mounting Debt Crisis 
LG Electronics Posts Record Q1 Revenue Amid Strong Demand and Cost Improvements 
Foreign Investors Pour $18.65 Billion into Japanese Stocks Amid Market Stabilization 
Ford Issues Major Recall on Over 422,000 Vehicles Due to Windshield Wiper Defect 
UAE's Largest Natural Gas Facility Suspended After Attack-Triggered Fire 
Alibaba Shares Slide as Jefferies Slashes Price Target Over AI Spending and Business Losses 
Chalco Stock Surges as Q1 2025 Profit Forecast Jumps Up to 58% 
Apple's Foldable iPhone Faces Engineering Setbacks, Mass Production Timeline at Risk 
Deere & Company Agrees to $99 Million Settlement Over Right-to-Repair Dispute 
NEW YORK, Nov. 14, 2016 -- The following statement is being issued by Levi & Korsinsky, LLP:
To: All persons or entities who purchased or otherwise acquired securities of Taro Pharmaceutical Industries Ltd. (“Taro Pharmaceutical”) (NYSE:TARO) between July 3, 2014 through September 9, 2016. You are hereby notified that a securities class action lawsuit has been commenced in the USDC for the Southern District of New York. To get more information go to:
http://www.zlk.com/pslra/taro-pharmaceutical-industries-ltd
or contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.
The complaint alleges that during the Class Period, Taro Pharmaceutical made false and/or misleading statements and/or failed to disclose material information, including that since 2014, Taro Pharmaceutical has violated federal antitrust laws by colluding with other pharmaceutical companies to keep the price of generic products artificially high.
On September 9, 2016, Taro Pharmaceutical disclosed the receipt of grand jury subpoenas in connection with a federal antitrust investigation into generic drug pricing. Then on October 17, 2016, an antitrust class action was filed against Taro Pharmaceutical and several other companies alleging they have engaged in the price-fixing of the generic drug Clobetasol since 2014.
If you suffered a loss in Taro Pharmaceutical you have until December 27, 2016 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky is a national firm with offices in New York, New Jersey, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Levi & Korsinsky, LLP Joseph E. Levi, Esq. 30 Broad Street - 24th Floor New York, NY 10004 Tel: (212) 363-7500 Toll Free: (877) 363-5972 Fax: (212) 363-7171 www.zlk.com
